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Abstract
Background: Despite intensive anti-hypertensive treatment, overall control rates of only 30 ~ 50 % have been
reported in patients with hypertension (HTN). However, clinical significance and angiographic characteristics of
patients with uncontrolled HTN following Below-the-knee arteries (BTK) interventions in patients with critical limb
ischemia (CLI) are not clarified yet as compared to those with controlled HTN.
Methods: A total 165 consecutive hypertensive patients with BTK lesions from August 2004 to November 2012
were enrolled for this study. Uncontrolled HTN was defined as a blood pressure of > 140 mmHg systolic and
90 mmHg diastolic under anti-hypertensive treatment. A total of 112 patients (67.8 %) had uncontrolled HTN. We
compared the clinical and angiographic characteristics of patients with uncontrolled HTN following BTK
interventions to those with controlled HTN at 12-month follow-up.
Results: The baseline characteristics are well balanced between the two groups. At 12 months, there was no
difference in the incidence of mortality, target lesion revascularization (TLR), target extremity revascularization (TER),
and limb salvage rate in both groups. However, amputation rates were higher in patients with controlled HTN
(33.9 vs. 19.6 %, P = 0.045).
Conclusion: Regardless of blood pressure control, HTN itself was an independent risk factor for BTK lesions, suggesting
more intensive medical therapy with close clinical follow up will be required for all BTK patients with HTN.
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Background
Hypertension (HTN) is probably the most common risk
factor of atherosclerotic cardiovascular disease. Athero-
sclerotic cardiovascular disease is the leading cause of
mortality in Western countries [1]. Peripheral arterial
disease (PAD), which is usually defined as atherosclerotic
occlusion of the arterial bed in the lower extremities, is
a major manifestation of systemic atherosclerosis. It is
well known that PAD is associated with increased risk of
mortality from cardiovascular disease (CVD) and all
causes such as cerebrovascular diseases, renal disease,
and diabetes mellitus (DM). In addition, it is an inde-
pendent risk factor for mortality and morbidity in pa-
tients with CVD [2–4]. Therefore, the clinical
importance of PAD has increasingly been acknowledged
in recent several years [5].
Critical limb ischemia (CLI), characterized by ischemic
rest pain or tissue loss, represent the most advanced
state of PAD, burdened by high morbidity and mortality.
CLI generally occurs in high risk patients with several
risk factors including DM, older age, HTN with exten-
sive atherosclerotic disease of below-the-knee vessels.
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Previous study also showed that PAD is significantly as-
sociated with systolic hypertension in the high risk
group [6].
HTN currently affects 25 % of adults and may
affect > 90 % of individuals during their lifetimes [7].
Therefore adequate control of blood pressure is of
public health importance. However, recent studies in-
dicated that 30 ~ 50 % of those with HTN are either
untreated or under-treated [8]. No previous study of
PAD has been performed in patients with uncon-
trolled HTN. Clinical significance and angiographic
characteristics of patients with uncontrolled HTN fol-
lowing Below-the-knee arteries (BTK) interventions in
patients with CLI are not clarified yet as compared to
those with controlled HTN.
In this study, we sought to clarify the impact of uncon-
trolled HTN on clinical outcomes in patients with CLI fol-
lowing BTK interventions during 12 months follow-up.
Methods
Study population
We performed peripheral angiography (PAG) in 180
consecutive patients (male 76.7 %, mean age 67.1 ±
10.9 years) who had typical or atypical claudication or
wound to confirm significant PAD at cardiovascular cen-
ter in Korea University Guro Hospital, Seoul, South
Korea.
From August 2004 to November 2012, all consecutive
hypertensive patients with CLI undergoing angioplasty
of at least 1 BTK vessel at our center were screened for
enrollment. Inclusion criteria were the presence of
hypertension, CLI (Rutherford class 4 or greater), sten-
osis or occlusion ≥ 40 mm of at least 1 tibial vessel with
distal run-off to the foot, and agreement to 12-month
angiographic evaluation.
The patients were excluded if they had one of the fol-
lowing conditions including advanced heart failure (New
York Heart Association class III or IV), serum creatin-
ine ≥ 3 mg/dL, life expectancy < 1 year, contraindication
to combined antiplatelet treatment, planned major am-
putation before angiography because these conditions
can be major causes of adverse cardiovascular events
and could serve as the bias of PAD and the patients
without HTN.
Finally, a total 165 hypertensive patients (91.6 % of
total subjects underwent PAG) with angiographic
proven PAD were enrolled for this study and under-
went peripheral angioplasty. Those patients were di-
vided into two groups according to blood pressure
(BP) control (controlled HTN group; n = 53 patients,
uncontrolled HTN group; n = 112 patients) and
analyzed. The study flow chart was shown in Fig. 1.
We compared the clinical and angiographic character-
istics, and major clinical outcomes after BTK
interventions up to 12 months in patients with HTN
according to presence of BP control.
Study definition
Hypertension was defined as either systolic or dia-
stolic elevation of blood pressure ≥ 140/90 mmHg or
ongoing antihypertensive pharmacological treatment.
The physician measured blood pressure with sphyg-
momanometer with patients in a sitting posture, after
resting for at least 5 min with the cuff placed on the
arm. In each patient, the mean of two readings taken
at intervals of at least 2 min was used in the study.
The blood pressures were measured for all patients
every three months from the enrollment. Uncon-
trolled HTN was defined as a blood pressure of >
140 mmHg systolic and 90 mmHg diastolic under
anti-hypertensive treatment including patients who
lack blood pressure control secondary to poor adher-
ence and/or an inadequate treatment regimen, as well
as those with true treatment resistance. Dyslipidemia
was defined as a total cholesterol level ≥ 200 mg/dL
or current treatment with lipid-lowering drugs.
Current smoking was defined as active smoking
within the past 12 months. Diabetes mellitus (DM)
was defined as the fasting blood glucose level ≥
126 mg/dL, or use of oral hypoglycemic agents or in-
sulin. In the present study, if a patient’s past history,
medical records, present symptoms or medical exam-
ination results accorded with one of the following cri-
teria, the patients were diagnosed with PAD: (1)
Claudication with ankle brachial indices < 0.90; (2)
Fig. 1 Flow chart
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Claudication with findings of a significant lesion
(≥70 % diameter stenosis) in peripheral artery on
computed tomographic angiography (CTA) or invasive
angiography; (3) Symptomatic carotid, subclavian ar-
terial disease (≥70 % diameter stenosis) documented
by image studies including CTA or invasive angiog-
raphy. Insignificant CAD was defined as the ≤30 %
diameter stenosis in peripheral arteries documented
by image studies including CTA or invasive
angiography.
Study procedure
After admission, the femoral, popliteal, dorsalis pedis
and posterior tibial arteries were palpated, and the ex-
tent of tissue loss was recorded as part of the pre-
procedural study. Angioplasties were performed with
crossover approach or an anterograde ipsilateral ap-
proach using 5 ~ 6 French sheaths. In case of failure
to recanalize by either intraluminal or subintimal ap-
proach, a retrograde approach was attempted. After
placing the sheath, intra-arterial heparin (70 IU/kg
heparin) was routinely administered via the vascular
sheath. A 0.014-in. guide wire was advanced into the
lesion and a balloon catheter of optimal size was in-
troduced. The appropriate balloon length and diam-
eter were determined by visual assessment. Balloon
inflation with normal pressure was maintained for at
least 120 s. All patients were taking aspirin 100 mg
daily at least 1 week prior to peripheral angioplasty.
Post-intervention dual antiplatelet therapy with aspirin
100 mg and clopidogrel 75 mg once daily or add-
itional cilostazol 100 mg twice a day were given at
least for 4 weeks, and 100 mg aspirin was given daily
thereafter.
Technical success was defined as restoration of dir-
ect flow in the target vessel with run-off to the foot
and a residual stenosis < 30 %. Clinical success was
defined as technical success without clinical events
during hospitalization. In patients with bilateral CLI,
an additional procedure for the revascularization of
the contralateral limb was planned in a different
session to limit the risk of x-ray exposure and con-
trast induced nephropathy, maintaining the same
randomization arm.
Follow-up
Once discharged, patients were followed up in Korea
University Guro Hospital. Office visits were scheduled
every two weeks for first 2 months, once a month for
the third month, and then every 3 months. Minor
amputations planned before the interventions were
performed 2 to 4 weeks after revascularization an in-
cluded toe amputations resulting from necrosis or
infection of tissues and bones with preservation of
healthy surrounding tissue. All patients were sched-
uled to be readmitted for control peripheral angiog-
raphy at 12 months. In case of clinical CLI
recurrence, angiography and repeat revascularization
were performed within 1 week from diagnosis. In pa-
tients undergoing clinically driven repeat angiography
of the target limb between 9 and 12 months who did
not show evidence of restenosis of the target lesion,
scheduled angiography at 12 months was not
performed.
Study End points and definitions
Before the intervention, immediately after the inter-
vention, and at follow-up, angiography of the target
vessel was performed in identical projections. The tar-
get lesion was identified by an image of the vascular
anatomy and specific landmarks (collaterals, bone
landmarks), with a second image showing the inflated
balloons. These images were compared with follow-up
angiograms.
The primary end point of the study was the com-
parison of the 12-month binary restenosis rates ac-
cording to BP control. Restenosis was defined by
angiography as a reduction in the luminal diameter >
50 % according to the worst angiographic view within
the treated lesion plus the 10-mm segments proximal
and distal to it.
The pre-specified secondary end points of the
study were (1) clinically driven target lesion revascu-
larization (TLR) defined as repeat percutaneous inter-
vention or surgical bypass graft resulting from
angiographic evidence of restenosis at the level of
the treated lesion ±10 mm in the presence of at least
1 of the following criteria: recurrence of pain in the
foot at rest that increased in the supine position, re-
currence of foot lesion or evidence during follow-up
of foot lesion size decrease–increase behavior or ap-
pearance of a new foot lesion; (2) major amputation,
defined as unplanned amputation of the target limb
in which a prosthesis was required for standing or
walking, however, if the patients who refused the am-
putation, those patients were excluded from the ana-
lysis to reduce bias; and (3) target vessel occlusion
(by CTA or invasive angiography). Acquired angio-
grams were reviewed by 2 blinded investigators who
did not actively participate in recruitment and had
no knowledge of clinical status and randomization
group.
Multivariate analyses was performed for the cumu-
lative 12-month prevalence of major adverse limb
events (MALE) including total death, major amputa-
tions, TLR, and repeat BTK interventions in both
groups.
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Statistical analysis
Data were analyzed according to the established stan-
dards descriptive statistics. Results were presented as
numbers (percentages) of patients or medians (inter-
quartile range) where applicable. Differences between
groups stratified by blood control status in patients with
HTN under anti-hypertensive medications were tested
by x2 test and the Fisher’s exact test for dichotomous
variables and the Mann–Whitney U test for continuous
variables. Then, differences in clinical outcome between
controlled HTN and Uncontrolled HTN groups were
assessed at 12-months follow-up. Results were adjusted
for age, gender and DM by logistic regression analysis.
The difference in MALE between two groups during
follow-up period was assessed by the Kaplan-Meier
method by means of the log-rank test. All tests were 2-
tailed and a p value of <0.05 was considered statistically
significant. All statistical analysis was performed by
means of SPSS 18.0 (SPSS Inc., Chicago, Illinois).
Results
The baseline clinical characteristics and laboratory find-
ings of patients are shown in Table 1. The most of vari-
ables including age, body mass index, dyslipidemia,
smoking history, chronic kidney disease, congestive heart
failure, and coronary artery disease were balanced be-
tween the two groups. There was no difference in base-
line laboratory findings between the two groups.
Coronary angiographic and clinical parameters were
shown in Table 2. There was no difference in coronary
angiographic characteristics between the two groups.
The frequencies of beta blockers (BB), angiotensin
converting enzyme inhibitor (ACEi), angiotensin recep-
tor blocker (ARB), statins and antiplatelet drugs were
similar between the two groups on admission and
30 days after BTK interventions in Table 3.
The procedural and peripheral angiographic character-
istics at baseline are shown in the Table 4. The most fre-
quently treated vessel was the anterior tibial artery. The
incidences of severe calcification, chronic total occlusion
(CTO) and proximal lesions were higher in the uncon-
trolled HTN group. However, Rutherford classifications,
ABI, lesion types, lesions length and procedural ap-
proach were similar between the two groups. Technical
and clinical successes were obtained in 94 % of all
patients.
Table 5 shows the procedural complications after
BTK interventions. There was no difference in pro-
cedural complications including arterio-venous (AV)
fistula, pseudo-aneurysm, access site hematoma,
gastro-intestinal (GI) bleeding, blood transfusion rates,
contrast induced nephropathy and arrhythmia be-
tween the two groups.
Clinical and peripheral angiographic data at 12 months
are presented in Table 6. There was no difference in the
incidence of mortality, myocardial infarction, cerebro-
vascular infarction in both groups. The incidences of
TLR, target extremity revascularization (TER), limb sal-
vage rate, binary restenosis, primary and secondary pa-
tency were also similar between the two groups at
12 months. And there was no patient who refused the
amputation, if the patients were indicated. However, all
patients with HTN (n = 165) had higher incidence of
MALE compared to those without HTN (n = 15) at
12 month follow-up (37.6 % vs. 6.7 %, P = 0.021).
In univariate analysis, HTN, DM foot, regional wall mo-
tion abnormality of LV, mitral valve calcification, congest-
ive heart failure, chronic kidney disease and dialysis were
significantly associated with MALE in patients with CLI
after peripheral angioplasty at 12 months. In multivariate
analysis, HTN (P = 0.002), mitral valve calcification (P =
0.040) and dialysis (P = 0.029) were independent risk fac-
tors for MALE (Table 7) at 12 months.
Kaplan-Meier curves showed that event free survivals
of MALE are similar in both groups at 12 month follow-
up (P = 0.456; Fig. 2).
Discussion
The main findings of the present study are that despite
the patients with uncontrolled HTN had more proximal
target lesions, higher incidences of CTO and severe cal-
cifications, however, at 12 month follow-up, there was
no difference in the incidence of mortality, TLR, TER,
limb salvage rate in both groups following successful
BTK endovascular revascularization. Rather, the amputa-
tion rate was higher in patients with controlled HTN
compared to that of uncontrolled HTN. Therefore, it is
difficult to interpret the difference in the results of the
impact of BP control on mid-term clinical outcomes in
hypertensive patients with CLI following BTK interven-
tions. However, HTN itself was an independent risk fac-
tor for MALE in hypertensive CLI patients with BTK
lesions, suggesting more intensive medical therapy with
close clinical follow up will be required for all patients
with HTN in real world clinical practice.
Previous study reported that the prevalence of PAD in
patients with HTN is higher than those without
HTN.[4] Essential HTN is associated with impaired
regulation of vascular tone and endothelial dysfunction
in the peripheral artery [9]. Evidence from these studies
suggests that acetylcholine mediated as well as flow-
mediated dilation is impaired in essential HTN and that
the dysfunction in part is related to defects in the nitric
oxide system [10, 11].
Guidelines published for the detection and treatment
of HTN (The joint National Committee on Prevention,
Detection, Evaluation and Treatment of high Blood
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Table 1 Baseline characteristics according to blood pressure control
Variable. n% Total (n = 165 Pts) (n = 201 Limb)
(n = 246 Lesion)
Controlled HTN (n = 53 Pts)
(n = 66 Limb) (n = 90 Lesion)
Uncontrolled HTN (n = 112 Pts)
(n = 135 Limb) (n = 156 Lesion)
P Value
Baseline characteristics
Gender (Male) 128 (77.5) 43 (81.1) 85 (75.8) 0.550
Age (years) 68.2 ± 9.3 68.8 ± 10.2 67.9 ± 8.8 0.549
Body mass index (kg/m2) 23.2 ± 3.2 22.9 ± 3.4 23.3 ± 3.1 0.471
Diagnosis
Wound 135 (81.8) 44 (83) 91 (81.2) 0.783
Diabetic foot ulcer 124 (75.1) 41 (77.3) 83 (74.1) 0.652
Gangrene 11 (6.6) 3 (5.6) 8 (7.1) 1.000
Claudication 12 (7.2) 5 (9.4) 7 (6.2) 0.525
Resting pain 16 (9.6) 3 (5.6) 13 (11.6) 0.228
Blood pressure; BP (mmHg)
Systolic BP 151.7 ± 17.3 122.6 ± 13.2 165.4 ± 19.2 <0.001
Diastolic BP 76.2 ± 45.5 64.9 ± 12.4 81.5 ± 61.2 0.053
Heart rate 78.9 ± 14.7 79.1 ± 19.5 78.8 ± 12.4 0.911
Pulse pressure (mmHg) 78.6 ± 24.2 57.7 ± 0.8 83.8 ± 42.0 <0.001
Past medical and social history
Known HTN 116 (70.6) 35 (66.2) 81 (73.2) 0.399
Diabetes 152 (92.1) 49 (92.4) 103 (91.9) 1.000
Dyslipidemia 8 (4.8) 3 (5.6) 5 (4.4) 0.713
Cerebrovascular disease 32 (19.3) 9 (16.9) 23 (20.5) 0.676
Chronic kidney disease 55 (33.3) 20 (37.7) 35 (31.2) 0.480
Dialysis 41 (24.8) 15 (28.3) 26 (23.2) 0.563
Atrial fibrillation 15 (9.0) 5 (9.4) 10 (8.9) 1.000
Coronary artery disease 102 (61.8) 29 (54.7) 73 (65.1) 0.231
Myocardial infarction 10 (6.0) 3 (5.6) 7 (6.2) 1.000
PTCA 24 (14.5) 6 (11.3) 18 (16.0) 0.486
CABG 10 (6.0) 1 (1.8) 9 (8.0) 0.170
Smoking 66 (40.0) 21 (39.6) 45 (40.1) 1.000
Current smokers 35 (21.2) 13 (24.5) 22 (19.6) 0.542
Alcoholic 49 (29.6) 17 (32.0) 32 (28.5) 0.716
Current alcoholics 29 (17.5) 11 (20.7) 18 (16.0) 0.513
Laboratory findings
Fasting glucose (mg/dL) 144.2 ± 67.2 150.2 ± 71.9 141.2 ± 65.0 0.520
Hemoglobin A1c (%) 7.4 ± 1.4 7.3 ± 1.3 7.5 ± 1.4 0.318
Total cholesterol (mg/dL) 147.6 ± 44.7 146.6 ± 48.5 148.1 ± 42.9 0.842
Triglycerides (mg/dL) 129.6 ± 100.5 132.0 ± 53.0 128.4 ± 124.1 0.840
HDL cholesterol (mg/dL) 36.3 ± 11.5 35.9 ± 12.3 36.6 ± 11.2 0.725
LDL cholesterol (mg/dL) 90.0 ± 37.3 89.0 ± 38.2 90.5 ± 36.9 0.819
hsCRP (mg/L) 20.3 ± 38.6 25.3 ± 37.5 18.0 ± 39.1 0.439
Albumin (g/dL) 3.8 ± 1.6 4.1 ± 4.0 3.6 ± 0.5 0.400
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Pressure, and European Society of Cardiology) recom-
mend PAD as evidence of clinical cardiovascular disease.
Hypertensive patients with PAD need drug therapy no
matter which stages of hypertension they are in [12].
However, due to the lack of specific PAD symptoms,
clinical awareness of PAD is very low in the primary care
setting, which translates into missed opportunities to
treatment of HTN in hypertensive patients with PAD.
Even though the hypertensive patients knew that they
had high blood pressure, 30 ~ 50 % of those with HTN
are either untreated or undertreated [8].
Previous meta-analyses of randomized placebo-
controlled trials indicate that antihypertensive therapy in
patients with uncontrolled HTN reduces the risk of
major cardiovascular adverse events (stroke by 30 %,
coronary heart disease by 10 % to 20 %, congestive heart
failure by 40 %, and total mortality by 10 %) [13], which
can be conversely interpreted that uncontrolled HTN
can be very important risk factor for cardiovascular ad-
verse events. Although, it remains controversial whether
the risk of cardiovascular events is related solely to the
blood pressure achieved or also to the manner in which
it is achieved [7]. And recent study also reported that
the risk of PAD was increased with increasing HTN
grade (HTN grade 3, OR 1.62, P = 0.006) [14], and recent
national review reported that the hypertensive patients
with major lower extremity amputations had higher inci-
dence of below the knee amputations than above the
knee amputations, which is suggesting that HTN can
affect smaller and more distal vessels of lower extrem-
ities [15].
Therefore, we hypothesized that uncontrolled HTN
also can affect the mid or long term clinical outcomes
after BTK interventions in hypertensive patients with
CLI. This is the first study to compare the 12 months
clinical outcomes after BTK interventions in hyperten-
sive patients with according BP control.
CLI represents the most severe stage of peripheral vas-
cular disease, with complications of limb loss [16, 17].
The clinical presentations range from rest pain, ischemic
ulcers to gangrene. Apart from the potential loss of limb
which is usually evident at presentation, the co-existent
cardiovascular morbidity and mortality presents an even
greater threat. Previous longitudinal follow-up studies
have been shown that HTN is amongst the most import-
ant risk factors for PAD along with increasing age,
smoking, DM and dyslipidemia [18–20].
In this study, the peripheral angiographic characteris-
tics at baseline showed that the incidences of severe cal-
cification, CTO and proximal lesions were higher in the
Table 1 Baseline characteristics according to blood pressure control (Continued)
Uric acid (mg/dL) 5.5 ± 1.8 5.6 ± 1.6 5.4 ± 1.8 0.559
Creatinine (mg/dL) 2.6 ± 3.1 2.8 ± 3.1 2.5 ± 3.0 0.595
Magnesium (mEq/L) 1.7 ± 0.2 1.7 ± 0.2 1.7 ± 0.3 0.615
Values are mean ± SD (range). HTN indicates hypertension group, Pts patients, AF atrial fibrillation, PTCA percutaneous transluminal coronary angioplasty, HDL high
dense lipoprotein, LDL low dense lipoprotein, hs-CRP high sensitive C-reactive protein
Table 2 Coronary angiographic and clinical parameters according to blood pressure control
Coronary artery disease Total (n = 165 Pts) (n = 201 Limb)
(n = 246 Lesion)
Controlled HTN (n = 53 Pts)
(n = 66 Limb) (n = 90 Lesion)
Uncontrolled HTN (n = 112 Pts)
(n = 135 Limb) (n = 156 Lesion)
P Value
Stents implantation 57 (34.5) 20 (37.7) 37 (33.0) 0.601
Routine CAG 138 (83.6) 31 (77.5) 107 (85.6) 0.226
Lesion site
Left main 13 (9.4) 3 (6.8) 10 (10.6) 0.550
Left artery descending artery 59 (42.7) 19 (43.1) 40 (42.5) 1.000
Left circumflex artery 49 (35.5) 16 (36.3) 33 (35.1) 1.000
Right coronary artery 49 (35.5) 14 (31.8) 35 (37.2) 0.572
Multi-vessel disease 56 (33.9) 19 (35.8) 37 (33.0) 0.728
1VD 41 (24.8) 9 (16.9) 32 (28.5)
2VD 34 (20.6) 13 (24.5) 21 (18.7)
3VD 22 (13.3) 6 (11.3) 16 (14.2)
CTO lesion 23 (13.9) 6 (11.3) 17 (15.1) 0.633
Onsite elective PCI 43 (26.0) 16 (30.1) 27 (24.1) 0.450
Values are mean ± SD (range). HTN indicates hypertension group, Pts patients, CAG coronary angiography, 1VD 1 vessel disease, 2VD 2 vessel disease, 3VD 3 vessel
disease, CTO chronic total occlusion, PCI percutaneous coronary intervention
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uncontrolled HTN group, which is consistent with the
previous reports that severe HTN was more strongly as-
sociated with proximal disease [21], and the most im-
portant factor influencing the progression of
atherosclerosis [22].
However, in this study, there was no difference in the
incidence of mortality, TLR, TER, limb salvage rate in
both groups at 12 months. Rather, amputation rate was
higher in patients with controlled HTN compared to
those with uncontrolled HTN (P = 0.045). Conversely,
the patients with uncontrolled HTN had a trend of
higher limb salvage rate than those with controlled HTN
(P = 0.059). Therefore, it is difficult to interpret this re-
sult. Our speculation and interpretations includes 1) dif-
ferences in amputation rates might be ‘by chance’ due to
relatively small number of study population, 2) signifi-
cant proportion of the controlled HTN pts might be as-
sociated with longer history of hypertension, causing
higher chance of advanced atherosclerosis and subse-
quent end organ damage, 3) despite of successful BTK
intervention, uncontrolled HTN group might have more
advanced wound condition that cannot be adjusted at
the time of presentation due to longer history of athero-
sclerotic vascular disease.
Among those with CLI enrolled in this study, there were
common peripheral angiographic features regardless of BP
control in both groups. More than half patients had above
the knee lesions, more proximal lesion sites, total occlu-
sion type of lesions in both groups and most of the pa-
tients (>90 %) had diffuse long lesions (≥2 cm), which are
consistent with the characteristics of unrecognized lower
extremity peripheral artery disease in hypertensive adults
[14]. And in this study, all patients with HTN (n = 165)
had higher incidence of MALE compared to those without
HTN (n = 15) at 12 month follow-up (37.6 % vs. 6.7 %, P
= 0.021). In this regard, we can postulate that HTN itself
is an independent risk factor for BTK lesions in patients
with CLI, regardless of BP control.
Increased pulse pressure (PP) is known to be associ-
ated with arterial stiffness, leading to increased arterial
pulse wave velocity. This causes a faster reflection of sys-
tolic pulse waves from the peripheral artery and causes a
boost to late systolic BP, a greater fall in pressure in dia-
stole and an increased PP [23]. In hypertensive patients,
arterial compliance was reduced already with borderline
PAD and increasing arterial stiffness plays a major
pathophysiological role in the development of both in-
creased PP and atherosclerotic lesions in the peripheral
arteries [24]. In this study, the patients with uncon-
trolled HTN had increased PP compared to those with
controlled HTN (mean PP; 83.8 ± 42.0 vs. 57.7 ±
0.8 mmHg, P < 0.001) as expected. However, there was
no significant correlation between PP and 12-month
clinical outcomes after BTK interventions in
Table 3 Medications according to blood pressure control on admission and 30 days after BTK intervention
Variable. n% Total (n = 165 Pts) (n = 201 Limb)
(n = 246 Lesion)
Controlled HTN (n = 53 Pts)
(n = 66 Limb) (n = 90 Lesion)
Uncontrolled HTN (n = 112 Pts)
(n = 135 Limb) (n = 156 Lesion)
P Value
In-hospital medications
Aspirin 165 (100.0) 53 (100.0) 112 (100.0) 1.000
Clopidogrel 152 (92.1) 48 (90.5) 104 (92.8) 0.758
Cilostazol 81 (49) 28 (52.8) 53 (47.3) 0.617
Warfarin 12 (7.2) 3 (5.6) 9 (8.0) 0.753
Sarpogrelate 61 (36.9) 21 (39.6) 40 (35.7) 0.730
Diuretics 41 (24.8) 11 (20.7) 30 (26.7) 0.446
ß-blockers 58 (35.1) 21 (39.6) 37 (33) 0.485
Ca-blockers 84 (50.9) 29 (54.7) 55 (49.1) 0.510
ACE-inhibitors 36 (21.8) 10 (18.8) 26 (23.2) 0.687
ARBs 73 (44.2) 25 (47.1) 48 (42.8) 0.618
Statins 114 (69) 39 (73.5) 75 (66.9) 0.472
30 days medications
Aspirin 155 (93.9) 52 (98.1) 103 (91.9) 0.170
Clopidogrel 140 (84.8) 48 (90.5) 92 (82.1) 0.244
Cilostazol 54 (32.7) 20 (37.7) 34 (30.3) 0.377
Warfarin 10 (6.0) 3 (5.6) 7 (6.2) 1.000
Sarpogrelate 60 (36.3) 21 (39.6) 39 (34.8) 0.605
Values are mean ± SD (range). BTK indicates Below-the-knee, HTN hypertension, Pts patients, ACE angiotensin converting enzyme, ARB angiotensin II
receptor blocker
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Table 4 Peripheral angiographic and clinical parameters of target lesions according to blood pressure control
Variable. n% Total (n = 165 Pts) (n = 201 Limb)
(n = 246 Lesion)
Controlled HTN (n = 53 Pts)
(n = 66 Limb) (n = 90 Lesion)
Uncontrolled HTN (n = 112 Pts)
(n = 135 Limb) (n = 156 Lesion)
P Value
Ankle-brachial index 0.65 ± 0.4 0.72 ± 0.48 0.62 ± 0.4 0.159
Rutherford classifications (Limb) 5.01 ± 1.48 5.12 ± 1.41 4.95 ± 1.52 0.453
Limb site
Right 108 (65.4) 35 (66.0) 73 (65.1) 1.000
Left 93 (56.3) 31 (58.4) 62 (55.3) 0.739
Both 36 (21.8) 13 (24.5) 23 (20.5) 0.552
Lesion locations
Above the knee - Pts 82 (49.6) 25 (47.1) 57 (50.8) 0.739
Above the knee - Limb 88 (43.7) 26 (39.3) 62 (45.9) 0.450
lliac - Pts 10 (6.0) 4 (7.5) 6 (5.3) 0.728
lliac - Limb 10 (4.9) 4 (6.0) 6 (4.4) 0.732
Femoral - Pts 77 (46.6) 24 (45.2) 53 (47.3) 0.868
Femoral - Limb 83 (41.2) 25 (37.8) 58 (42.9) 0.543
Popliteal - Pts 20 (12.1) 5 (9.4) 15 (13.3) 0.612
Popliteal - Limb 21 (10.4) 6 (9.0) 15 (11.1) 0.808
Below the knee - Pts
Below the knee - Limb
Tibial - Pts 156 (94.5) 49 (92.4) 107 (95.5) 0.470
Tibial - Limb 183 (91.0) 57 (86.3) 126 (93.3) 0.119
ATA - Pts 119 (72.1) 37 (69.8) 82 (73.2) 0.711
ATA - Limb 140 (69.6) 43 (65.1) 97 (71.8) 0.333
PTA - Pts 74 (44.8) 25 (47.1) 49 (43.7) 0.739
PTA - Limb 76 (37.8) 26 (39.3) 50 (37.0) 0.759
Peroneal - Pts 44 (26.6) 16 (30.1) 28 (25.0) 0.572
Peroneal - Limb 47 (23.3) 17 (25.7) 30 (22.2) 0.598
Lesion site
Proximal 151 (61.3) 45 (50.0) 106 (67.9) 0.007
Mid 30 (12.1) 15 (16.6) 15 (9.6) 0.110
Distal 24 (9.7) 12 (13.3) 12 (7.6) 0.182
Ostium 42 (17) 19 (21.1) 23 (14.7) 0.221
Lesion type
Concentric 38 (15.4) 16 (17.7) 22 (14.1) 0.467
Eccentric 61 (24.7) 20 (22.2) 41 (26.2) 0.541
Total occlusion 147 (59.7) 54 (60.0) 93 (59.6) 1.000
Lesion characteristics
CTO 119 (48.3) 35 (38.8) 84 (53.8) 0.025
Diffuse (≥2 cm) 231 (93.9) 83 (92.2) 148 (94.8) 0.418
Calcification 119 (48.3) 36 (40.0) 83 (53.2) 0.048
Procedure
SubIntimal approach 57 (23.1) 23 (25.5) 34 (21.7) 0.532
POBA 228 (92.6) 84 (93.3) 144 (92.3) 1.000
Stent type 18 (7.3) 6 (6.6) 12 (7.6) 1.000
Smart control 1 (0.4) 1 (1.1) 0 (0.0)
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hypertensive patients with CLI according to BP control
(P = 0.497).
Study limitation
This study has several obvious limitations. First, we used
retrospective analysis, although this study was performed
as a prospective study. However, this study results is still
meaningful due to the nature of study. We cannot per-
form randomized clinical trial with this exact title in
terms of ethical issues.
Second, Uncontrolled HTN was defined as a blood
pressure of > 140 mmHg systolic and 90 mmHg diastolic
under anti-hypertensive treatment including patients
who lack blood pressure control secondary to poor ad-
herence and/or an inadequate treatment regimen, as well
as those with true treatment resistance, which can be
limitations due to the difference of pathophysiology be-
tween inadequate treatment and true treatment resist-
ance. However, in this study, we showed that regardless
of blood pressure control, HTN itself was an independ-
ent risk factor for MALE in CLI patients with BTK le-
sions. Third, there are small numbers of patients
without HTN, which could be too small to compare with
those with HTN. However, this study is retrospective ob-
servational study for the patients who underwent the
peripheral angioplasties. Therefore, we could not enroll
the patients without hypertension as a control group.
Further a prospective study should be considered to get
final conclusion.
Fourth, similar to many other trials in interventional
cardiology, this was not a blinded study. In addition, pa-
tients were enrolled only in a single, high volume center
that might have unique patient referral pattern and
interventional technique. Fifth, even though we mini-
mized the confounding effects from the baseline biases
with multivariate logistic analysis, it is possible that
some potential confounders might have crept in. Sixth,
this study had no financial support, and no external
angiography was available for adjudication of the end
points. However, the size of the observed effect of un-
controlled HTN in the BTK lesions leaves few chances
for these results to be controverted in a multicenter, ran-
domized study. Finally, clinical results achieved by an in-
tegrated multidisciplinary approach to CLI in well-
organized specialized center may not be reproduced in
patients with uncontrolled HTN in other centers with
different organization.
Conclusions
Even though the patients with uncontrolled HTN had
more proximal target lesions, higher incidences of CTO
and severe calcifications, there was no difference in the
Table 4 Peripheral angiographic and clinical parameters of target lesions according to blood pressure control (Continued)
Xpert 14 (5.6) 3 (3.3) 11 (7.0)
Chromis deep 2 (0.8) 2 (2.2) 0 (0.0)
Maris deep 1 (0.4) 0 (0.0) 1 (0.6)
Technical Success 230 (93.4) 82 (91.1) 148 (94.8) 0.287
Clinical Success 232 (94.3) 85 (94.4) 147 (94.2) 1.000
Values are mean ± SD (range). HTN indicates hypertension group, Pts patients, ATA anterior tibial artery, PTA posterior tibial artery, CTO chronic total occlusion,
POBA plain old balloon angioplasty
Table 5 Periprocedural complications according to blood pressure control
Type of complications Total (n = 165 Pts) (n = 201 Limb)
(n = 246 Lesion)
Controlled HTN (n = 53 Pts)
(n = 66 Limb) (n = 90 Lesion)
Uncontrolled HTN (n = 112 Pts)
(n = 135 Limb) (n = 156 Lesion)
P Value
AV fistula 1 (0.6) 1 (1.8) 0 (0.0) 0.321
Pseudo-aneurysm 2 (1.2) 1 (1.8) 1 (0.8) 0.541
Access site hematoma
minor (<4 cm) 4 (2.4) 1 (1.8) 3 (2.6) 1.000
Major (≥4 cm) 14 (8.4) 4 (7.5) 10 (8.9) 1.000
G.I. bleeding 4 (2.4) 0 (0.0) 4 (3.5) 0.307
Transfusion 91 (55.1) 31 (58.4) 60 (53.5) 0.617
Transfusion (Unit) 5.81 ± 10.4 6.9 ± 11.2 5.2 ± 10.0 0.325
Acute renal failure 4 (2.4) 1 (1.8) 3 (2.6) 1.000
Congestive heart failure 3 (1.8) 1 (1.8) 2 (1.7) 1.000
Arrhythmia 4 (2.4) 2 (3.7) 2 (1.7) 0.594
Values are mean ± SD (range). HTN indicates hypertension group, Pts patients, AV arterio-venous, G.I. gastrointestinal
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Table 6 Clinical outcomes following BTK interventions in patients with CLI according to blood pressure control at 12 months
Variable. n% Total (n = 165 Pts) (n = 201 Limb)
(n = 246 Lesion)
Controlled HTN (n = 53 Pts)
(n = 66 Limb) (n = 90 Lesion)
Uncontrolled HTN (n = 112 Pts)
(n = 135 Limb) (n = 156 Lesion)
P Value
12-months clinical outcomes
Mortality 9 (5.4) 2 (3.7) 7 (6.2) 0.720
Cardiac death 5 (3.0) 1 (1.8) 4 (3.5) 1.000
TLR, Pts 18 (10.9) 6 (11.3) 12 (10.7) 0.907
TLR, Limb 21 (10.4) 6 (9) 15 (11.1) 0.808
TER, Pts 20 (12.1) 7 (13.2) 13 (11.6) 0.769
TER, Limb 25 (12.4) 7 (10.6) 18 (13.3) 0.655
Non TER 7 (4.2) 3 (5.7) 4 (3.6) 0.534
Amputations - Pts 40 (24.2) 18 (33.9) 22 (19.6) 0.045
Amputations - Limb 41 (20.3) 19 (28.7) 22 (16.2) 0.061
Major
above the knee 0 (0.0) 0 (0.0) 0 (0.0) 1.000
above the ankle - Pts 10 (6.0) 7 (13.2) 3 (2.6) 0.013
above the ankle - Limb 10 (4.9) 7 (10.6) 3 (2.2) 0.016
minor (below the ankle) - Pts 30 (18.1) 11 (20.7) 19 (16.9) 0.556
minor (below the ankle) - Limb 31 (15.4) 12 (18.1) 19 (14) 0.533
Myocardial infarction 2 (1.2) 1 (1.8) 1 (0.8) 0.541
PTCA 7 (4.2) 3 (5.6) 4 (3.5) 0.682
Cerebrovascular accidents 1 (0.6) 0 (0.0) 1 (0.8) 1.000
Limb salvage 147/156 (94.2) 45/51 (88.2) 102/105 (97.1) 0.059
Angiogram to follow-up 55 (33.3) 18 (33.9) 37 (33) 0.906
CT 21 (38.1) 8 (44.4) 13 (35.1) 0.505
PAG 42 (76.3) 13 (72.2) 29 (78.3) 0.738
Binary restenosis 35 (63.6) 11 (61.1) 24 (64.8) 0.786
Total re-occlusion 29 (52.7) 8 (44.4) 21 (56.7) 0.391
Primary patency 20 (36.3) 7 (38.8) 13 (35.1) 0.786
Secondary patency 39 (70.9) 11 (61.1) 28 (75.6) 0.264
Non-Total occlusion; Runoff (≥1) included
Collateral, to distal
53 (96.3) 17 (94.4) 36 (97.2) 1.000
Values are mean ± SD (range). BTK indicates Below-the-knee artery, CLI critical limb ischemia, HTN hypertension, Pts patients, TLR target lesion revascularization,
TER target extremity revascularization, PTCA percutaneous transluminal coronary angioplasty, CT computed tomography, PAG follow-up invasive
peripheral angiography
Table 7 Univariate and multivariate Cox analyses for MALE in patients with CLI after peripheral angioplasty at 12-month follow-up
Univariate analysis Multivariate analysis
Variable. N (%) OR (95 % CI) P-Value OR (95 % C.I) P-Value
Hypertension (itself) 2.093 (1.106 – 4.098) 0.017 3.867 (1.625 – 9.199) 0.002
DM foot 1.903 (0.935 – 3.876) 0.076
RWMA 2.342 (1.190 – 4.608) 0.014
Mitral valve calcification 3.029 (1.297 – 7.073) 0.010 2.915 (1.048 – 8.107) 0.040
CHF 2.342 (1.190 – 4.608) 0.014
CKD 1.966 (1.049 – 3.685) 0.035
Dialysis 3.000 (1.496 – 6.014) 0.002 5.221 (1.184 – 23.02) 0.029
OR odds ratio, CI confidence interval, DM diabetes mellitus, RWMA reginonal wall motion abnormality, CHF congestive heart failure-systolic, CKD chronic
kidney disease
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incidence of major adverse events following BTK inter-
ventions in both groups at 12 months. Rather, the ampu-
tation rates were higher in patients with controlled HTN
compared to those of uncontrolled HTN and there were
common peripheral angiographic features regardless of
BP control in both groups. Regardless of blood pressure
control, HTN itself was an independent risk factor for
MALE in CLI patients with BTK lesions, suggesting
more intensive medical therapy with close clinical follow
up will be required in real world clinical practice.
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